Literature DB >> 33955799

miR-1/133a and miR-206/133b clusters overcome HGF induced gefitinib resistance in non-small cell lung cancers with EGFR sensitive mutations.

Demin Jiao1,2, Chunyan Jiang3, Linzhi Zhu1, Jie Zheng3, Xibang Liu1, Xiang Liu2, Jun Chen2, Xiali Tang2, Qingyong Chen1,2.   

Abstract

It has been reported that clustered miRNAs can be transcribed coordinately and exhibit similar functions by regulating the same targets. miR-1/133a and miR-206/133b are well-characterized miRNA clusters. However, the effect of these clusters on EGFR-TKI resistance is not clear. In this study, we demonstrated that lentivirus-mediated HGF overexpression was able to induce gefitinib resistance in non-small cell lung cancers with EGFR sensitive mutations. miR-1/133a and miR-206/133b clusters could overcome HGF induced gefitinib resistance. Furthermore, the clusters were more effective than individual miRNA. Transcriptome RNA sequencing and bioinformatics analysis revealed that multiple pathways, including 'EGFR tyrosine kinase inhibitor resistance' pathway, were involved in anti-resistance mechanisms of miR-1/133a and miR-206/133b clusters. Western blotting results confirmed the inhibitory effect of miRNA clusters on MET expression and downstream pathway activation. In conclusion, miR-1/133a and miR-206/133b clusters are able to exhibit the synergetic effect on overcoming HGF-induced gefitinib resistance in NSCLC and the mechanisms are through targeting multiple genes related to gefitinib resistance.

Entities:  

Keywords:  NSCLC; gefitinib; miR-1; miR-133a; miR-133b; miR-206; resistance

Mesh:

Substances:

Year:  2021        PMID: 33955799     DOI: 10.1080/1061186X.2021.1927054

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  1 in total

1.  Circular RNA SOX13 promotes malignant behavior and cisplatin resistance in non-small cell lung cancer through targeting microRNA-3194-3p/microtubule-associated protein RP/EB family member 1.

Authors:  Libin Zhang; Hao Peng; Zheyuan Xu; Qiuju Yang; Yang Wang; Han Wang; Liang Bu
Journal:  Bioengineered       Date:  2022-01       Impact factor: 3.269

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.